Results 181 to 190 of about 212,526 (280)

Bruton's tyrosine kinase inhibitors in diffuse large B-cell lymphoma therapy: critical considerations and future innovations. [PDF]

J Transl Med
Lu C, Chen Q, Shen Y, Chen M, Xie Y, Wang C, Yu L.   +6 more
europepmc   +1 more source

Bruton's tyrosine kinase inhibition in ITP: Wayrilz (rilzabrutinib) as a disease-modifying strategy. [PDF]

Ann Med Surg (Lond)
Hujjat SFZ, Chandani HK, Khan MS, Chandani DK, Mahmoud A.   +4 more
europepmc   +1 more source

CLRM-15 TRIAL IN PROGRESS: A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS-PENETRANT INHIBITOR OF BRUTON’S TYROSINE KINASE (BTKI) FOR RELAPSED/REFRACTORY PRIMARY/SECONDARY CNS LYMPHOMA (R/R PCNSL/SCNSL) AND PRIMARY VITREORETINAL LYMPHOMA (PVRL)

, 2022
Carole Soussain, Christian Grommes, Samar Issa, Renee Ward, Caryn Peterson, Matt Cravets, Anita Mathias, Judith Sosa, Brian J. Kirby, Zhaoqing Ding, Isharat Yusuf, Mark J. Rose, Marcos W Steinberg, Han W. Tun   +13 more
openalex   +1 more source

Case Report: Secondary neurolymphomatosis successfully treated with sequential Bruton's tyrosine kinase inhibitor and bispecific antibody therapy. [PDF]

Front Oncol
Oura M, Toho M, Ikeda D, Fukuda N, Torres AS, Fujii F, Sakuma H, Uehara A, Tabata R, Narita K, Takeuchi M, Matsue K.   +11 more
europepmc   +1 more source

Bruton’s tyrosine kinase (BTK) and matrix metalloproteinase-9 (MMP-9) regulate NLRP3 inflammasome-dependent cytokine and neutrophil extracellular trap responses in primary neutrophils [PDF]

Vinícius Nunes Cordeiro Leal, Francesca Bork, Maria Mateo Tortola, Juli-Christin von Guilleaume, Carsten Leo Greve, Stefanie Bugl, Bettina Danker, Zsofia A. Bittner, Bodo Grimbacher, Alessandra Pontillo, Alexander N.R. Weber   +10 more
openalex   +1 more source

Expression of Bruton's Tyrosine Kinase Reflects Immune Cells Infiltration and Cell Proliferation in Breast Cancer. [PDF]

World J Oncol
AlRammah T, Wu R, Chida K, Kawashima K, Hakamada K, Ishikawa T, Ebos JML, Takabe K.   +7 more
europepmc   +1 more source

Discovery of Pteridine-7(8H)-one Derivatives as Potent and Selective Inhibitors of Bruton’s Tyrosine Kinase (BTK)

, 2022
Dou Dou, Yanyan Diao, Wenjie Sha, Rongrong Su, Linjiang Tong, Wenjie Li, Limin Leng, Lijuan Xie, Zhixiao Yu, Haoming Song, Zihao Shen, Lili Zhu, Zhenjiang Zhao, Hua Xie, Zhuo Chen, Honglin Li, Yufang Xu   +16 more
openalex   +1 more source

Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma [PDF]

, 2017

core   +1 more source

UVI5008: the first reversible, non-covalent Bruton's tyrosine kinase epi-inhibitor for B-cell malignancies. [PDF]

J Hematol Oncol
Dell'Aversana C, Sgueglia G, Massaro C, Perricone U, Sarno F, Megchelenbrink WL, Conte M, Carafa V, Campanella A, Frenquelli M, Bordini J, Ghia P, Petrizzi VB, Alvarez R, Nappi D, Chiurazzi F, Tambaro FP, Wierda WG, de Lera AR, Altucci L.   +19 more
europepmc   +1 more source

A pharmacovigilance study of Bruton's tyrosine kinase inhibitors: a multidimensional analysis based on FAERS and VigiBase. [PDF]

Front Immunol
Qu H, Jia Y, Liu Z, Li Z, Zhao X, Wu Z, Fan G, Lou Y.   +7 more
europepmc   +1 more source